EI
BCRX icon

Ellevest Inc’s BioCryst Pharmaceuticals BCRX Stock Holding History

Ellevest Inc’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-233
Closed -$1.94K – 499
2023
Q1 		$1.94K Buy
+233
New +$2.24K ﹤0.01% 1448
2022
Q3 		– Sell
-96
Closed -$1K – 1607
2022
Q2 		$1K Buy
96
+93
+3,100% +$959 ﹤0.01% 1210
2022
Q1 		$0 Hold
3
– – ﹤0.01% 1419
2021
Q4 		$0 Sell
3
-55
-95% -$728 ﹤0.01% 1418
2021
Q3 		$1K Buy
58
+15
+35% +$237 ﹤0.01% 1230
2021
Q2 		$1K Buy
43
+40
+1,333% +$543 ﹤0.01% 1121
2021
Q1 		$0 Hold
3
– – ﹤0.01% 1262
2020
Q4 		$0 Sell
3
-28
-90% -$144 ﹤0.01% 1192
2020
Q3 		$0 Buy
31
+12
+63% +$51 ﹤0.01% 1139
2020
Q2 		$0 Buy
+19
New +$76 ﹤0.01% 1135

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Ellevest Inc's BCRX Position: Q2 2023 in Review

Ellevest Inc sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2023, closing a stake of 233 shares — an estimated $1.94K sold.

Ellevest Inc first reported a position in BCRX in Q2 2020 and held it in 10 quarters. The position peaked at $1.94K in Q1 2023. 236 funds tracked by Wall St. Rank hold BCRX as of Q2 2023.

  • Ellevest Inc reported no remaining BioCryst Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Ellevest Inc sold 233 BioCryst Pharmaceuticals shares in Q2 2023, an estimated $1.94K.
  • Ellevest Inc first reported a position in BioCryst Pharmaceuticals in Q2 2020 and held it in 10 quarters.
  • Ellevest Inc's BioCryst Pharmaceuticals position peaked at $1.94K in Q1 2023.
  • 236 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2023.

Based on Ellevest Inc's 13F filing for Q2 2023, filed 9 Aug 2023.